Alecta Tjanstepension Omsesidigt Sells 147,500 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Alecta Tjanstepension Omsesidigt sold 147,500 shares of Thermo Fisher, reducing its stake by 23.6% to 477,900 shares (about 0.13% of TMO, valued at $276.9M) and making the stock ~1.2% of Alecta's holdings (its 23rd largest position).
• Thermo Fisher beat Q1 estimates with EPS $5.44 vs $5.25 and revenue $11.01B vs $10.86B, set FY2026 EPS guidance of 24.640–25.120, and raised its quarterly dividend to $0.47.
• Analyst sentiment remains positive: two analysts rate TMO a Strong Buy, nineteen rate it Buy and two rate it Hold, giving an average consensus price target of $623.05.

Alecta Tjanstepension Omsesidigt reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 23.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 477,900 shares of the medical research company's stock after selling 147,500 shares during the period. Thermo Fisher Scientific makes up about 1.2% of Alecta Tjanstepension Omsesidigt's holdings, making the stock its 23rd largest holding. Alecta Tjanstepension Omsesidigt owned 0.13% of Thermo Fisher Scientific worth $276,924,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Fire Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 25.4% in the fourth quarter. Fire Capital Management LLC now owns 3,540 shares of the medical research company's stock worth $2,051,000 after acquiring an additional 718 shares during the period. Manske Wealth Management purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $213,000. Indivisible Partners purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $726,000. S Bank Fund Management Ltd raised its position in shares of Thermo Fisher Scientific by 1.4% in the fourth quarter. S Bank Fund Management Ltd now owns 21,000 shares of the medical research company's stock worth $12,168,000 after buying an additional 289 shares in the last quarter. Finally, Ballast Advisors LLC raised its position in shares of Thermo Fisher Scientific by 1.2% in the fourth quarter. Ballast Advisors LLC now owns 2,367 shares of the medical research company's stock worth $1,372,000 after buying an additional 28 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMO. Morgan Stanley reiterated an "overweight" rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. DZ Bank began coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a "buy" rating and a $610.00 price objective on the stock. Barclays lowered their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 14th. Citigroup increased their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Finally, Jefferies Financial Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $623.05.

Thermo Fisher Scientific Trading Up 1.5%

NYSE TMO opened at $473.79 on Thursday. The stock's 50-day simple moving average is $494.37 and its two-hundred day simple moving average is $547.16. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $176.07 billion, a price-to-earnings ratio of 26.05, a PEG ratio of 2.07 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter last year, the business posted $5.15 earnings per share. The company's revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a $0.47 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.34%.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 5,800 shares of company stock worth $2,963,544. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.